JP2023529701A5 - - Google Patents
Info
- Publication number
- JP2023529701A5 JP2023529701A5 JP2022576178A JP2022576178A JP2023529701A5 JP 2023529701 A5 JP2023529701 A5 JP 2023529701A5 JP 2022576178 A JP2022576178 A JP 2022576178A JP 2022576178 A JP2022576178 A JP 2022576178A JP 2023529701 A5 JP2023529701 A5 JP 2023529701A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- alkyl
- group
- aryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025137145A JP2025170326A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137144A JP2025168374A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036622P | 2020-06-09 | 2020-06-09 | |
| US63/036,622 | 2020-06-09 | ||
| US202063111429P | 2020-11-09 | 2020-11-09 | |
| US63/111,429 | 2020-11-09 | ||
| PCT/US2021/036657 WO2021252661A1 (en) | 2020-06-09 | 2021-06-09 | Allosteric egfr inhibitors and methods of use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025137145A Division JP2025170326A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137144A Division JP2025168374A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529701A JP2023529701A (ja) | 2023-07-11 |
| JP2023529701A5 true JP2023529701A5 (https=) | 2024-06-19 |
| JP7785701B2 JP7785701B2 (ja) | 2025-12-15 |
Family
ID=78846544
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576178A Active JP7785701B2 (ja) | 2020-06-09 | 2021-06-09 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137144A Pending JP2025168374A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137145A Pending JP2025170326A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025137144A Pending JP2025168374A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
| JP2025137145A Pending JP2025170326A (ja) | 2020-06-09 | 2025-08-20 | アロステリックｅｇｆｒ阻害剤及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230212171A1 (https=) |
| EP (1) | EP4161516A4 (https=) |
| JP (3) | JP7785701B2 (https=) |
| KR (1) | KR20230033645A (https=) |
| CN (1) | CN115811977A (https=) |
| AU (1) | AU2021289729A1 (https=) |
| BR (1) | BR112022025139A2 (https=) |
| CA (1) | CA3181982A1 (https=) |
| CO (1) | CO2022019316A2 (https=) |
| EC (1) | ECSP22098041A (https=) |
| IL (1) | IL298935A (https=) |
| JO (1) | JOP20220332A1 (https=) |
| MX (1) | MX2022015739A (https=) |
| NZ (1) | NZ795548A (https=) |
| SA (1) | SA522441639B1 (https=) |
| WO (1) | WO2021252661A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023289368A1 (en) * | 2022-06-21 | 2025-01-16 | Dana-Farber Cancer Institute, Inc. | Fused bicyclic egfr inhibitors and methods of use thereof |
| GB202216962D0 (en) | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005021963A1 (de) * | 2005-05-12 | 2006-11-23 | Aicuris Gmbh & Co. Kg | Substituierte Dihydropyrazolotriazinone |
| US8163779B2 (en) * | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| CA2684633A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
| JP5746032B2 (ja) * | 2008-09-19 | 2015-07-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ３，４−ジヒドロ−２Ｈ−ピロロ［１，２−ａ］ピラジン−１−オン誘導体 |
| JP6845165B2 (ja) * | 2015-06-30 | 2021-03-17 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｅｇｆｒ阻害剤およびその使用方法 |
| PE20211388A1 (es) * | 2018-06-29 | 2021-07-27 | Hoffmann La Roche | Compuestos |
| JP7086272B2 (ja) * | 2018-08-16 | 2022-06-17 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | イソインドリン－１－オン誘導体、同じものを調製する方法、およびがんを予防するまたは処置するための有効な構成要素として同じものを含む医薬組成物 |
-
2021
- 2021-06-09 US US18/000,722 patent/US20230212171A1/en active Pending
- 2021-06-09 NZ NZ795548A patent/NZ795548A/en unknown
- 2021-06-09 AU AU2021289729A patent/AU2021289729A1/en active Pending
- 2021-06-09 CA CA3181982A patent/CA3181982A1/en active Pending
- 2021-06-09 IL IL298935A patent/IL298935A/en unknown
- 2021-06-09 BR BR112022025139A patent/BR112022025139A2/pt unknown
- 2021-06-09 EP EP21821203.3A patent/EP4161516A4/en active Pending
- 2021-06-09 KR KR1020227043942A patent/KR20230033645A/ko active Pending
- 2021-06-09 JP JP2022576178A patent/JP7785701B2/ja active Active
- 2021-06-09 WO PCT/US2021/036657 patent/WO2021252661A1/en not_active Ceased
- 2021-06-09 MX MX2022015739A patent/MX2022015739A/es unknown
- 2021-06-09 CN CN202180041075.2A patent/CN115811977A/zh active Pending
-
2022
- 2022-12-07 SA SA522441639A patent/SA522441639B1/ar unknown
- 2022-12-08 JO JOJO/P/2022/0332A patent/JOP20220332A1/ar unknown
- 2022-12-28 EC ECSENADI202298041A patent/ECSP22098041A/es unknown
- 2022-12-30 CO CONC2022/0019316A patent/CO2022019316A2/es unknown
-
2025
- 2025-08-20 JP JP2025137144A patent/JP2025168374A/ja active Pending
- 2025-08-20 JP JP2025137145A patent/JP2025170326A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529701A5 (https=) | ||
| JP2021519783A5 (https=) | ||
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| RU2440330C2 (ru) | ПРОИЗВОДНЫЕ 4-(2-АМИНО-1-ГИДРОКСИЭТИЛ)ФЕНОЛА, КАК АГОНИСТЫ β2 АДРЕНЕРГИЧЕСКОГО РЕЦЕПТОРА | |
| JP2021512059A5 (https=) | ||
| JP2022547952A5 (https=) | ||
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2023520333A5 (https=) | ||
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| JP2022515198A5 (https=) | ||
| CN113316574A (zh) | Shp2抑制剂及其应用 | |
| JP2019518741A5 (https=) | ||
| JP2018504418A5 (https=) | ||
| DK2326329T3 (en) | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | |
| JP2020503299A5 (https=) | ||
| JP2021516232A5 (https=) | ||
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| AU2016257816A1 (en) | Process for preparing an anti-cancer agent, 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts | |
| JP2020507582A5 (https=) | ||
| JP2018505880A5 (https=) | ||
| JP2019507114A5 (https=) | ||
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2019519586A5 (https=) | ||
| JP2015529194A5 (https=) | ||
| KR20100131446A (ko) | Ｅｇｆｒ 의존성 질환 또는 ｅｇｆｒ 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도 |